Lotton

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lotton

Quick Facts

Property Description
Active ingredient Etodolac
Form Oral tablets or capsules (Systemic)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of musculoskeletal pain and inflammatory symptoms
Origin Synthetic (Pyranocarboxylic acid derivative)

Lotton (Etodolac): Definition and Pharmacological Classification

Lotton is a medicinal preparation containing the active ingredient Etodolac, which is clinically recognized as a synthetic member of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. This designation places it among agents used to modulate the inflammatory response throughout the body. Etodolac is chemically a pyranocarboxylic acid derivative designed for systemic action upon ingestion, distinguishing it from agents that act only locally. The classification as an NSAID confirms its primary role in controlling the biological processes that cause pain, swelling, and fever. This drug acts as an anti-inflammatory, analgesic, and antipyretic. This confirms the medicine is designed to reduce pain, ease swelling, and help lower fever.

Composition, Form, and General Therapeutic Purpose

The drug Lotton is formulated as a single-ingredient product designed for oral administration, typically available as tablets or capsules. The composition consists of the therapeutic agent Etodolac combined with the necessary inactive excipients required for the solid oral form. The general therapeutic purpose of this medication stems directly from its NSAID class action, which provides comprehensive symptomatic relief through its core capabilities. The drug's established mechanism involves the inhibition of prostaglandin synthesis. This mechanism is key to the drug's ability to help interrupt the chemical signals that cause pain and inflammation. The result is a powerful triple benefit: analgesia (pain relief), anti-inflammation (reducing swelling), and antipyresis (reducing fever), making it a comprehensive symptomatic treatment for inflammatory conditions.

Regulatory References

  1. FDA DailyMed Label

What side effects are possible with Lotton?

Possible Side Effects and Safety Information

The safety profile for Lotton is formally documented in government regulatory records, which categorize risks by frequency and severity. The most significant safety alerts involve the risk of serious complications affecting the gastrointestinal system.

Serious and Clinically Significant Risks

Official regulatory labeling includes a Boxed Warning to highlight the potential for infrequent but severe gastrointestinal adverse reactions. These include:

  • Ischemic Colitis: A condition involving reduced blood flow to the bowel, which may lead to significant complications.
  • Serious Complications of Constipation: Events such as intestinal obstruction, ileus, impaction, toxic megacolon, and secondary bowel ischemia have been documented. These serious events have resulted in hospitalization, and in rare cases, surgery, blood transfusion, and death.

Immediate and permanent discontinuation of the medicine is required if constipation or any signs of ischemic colitis occur.

Common Adverse Reactions

Adverse reactions observed at a higher rate (commonly) in clinical trials compared to placebo include gastrointestinal symptoms:

  • Constipation (the most frequently reported adverse reaction)
  • Abdominal discomfort and pain
  • Nausea

Safety Restrictions and Monitoring

The medicine is strictly contraindicated (prohibited) in patients with certain pre-existing conditions that increase the risk of serious complications. These conditions include a history of chronic or severe constipation or its sequelae (e.g., intestinal obstruction, perforation), a history of ischemic colitis, or severe hepatic impairment.

Population-Specific Warnings: Regulatory documents note that elderly and debilitated patients may have a greater risk for complications related to constipation and should be monitored with particular caution. Furthermore, the risk of constipation is related to the starting dosage; therefore, dose adjustments or immediate discontinuation are required based on the onset or recurrence of constipation to manage this known risk.

Overdose and Emergency Response

Lotton (Etodolac) overdose is defined by specific clinical signs and the potential for severe, life-threatening outcomes, as documented in official prescribing information.

Documented Overdose Manifestations

Manifestations often affect the central nervous system (CNS), presenting as drowsiness, headache, lack of energy, or dizziness. Gastrointestinal (GI) symptoms are also documented, including nausea, vomiting, and stomach pain.

Severe Outcomes and Emergency Action

In cases of significant overdose, the regulatory profile warns of severe complications involving major organ systems. These outcomes include the potential for kidney failure or liver damage. Profound neurological depression is also a risk, which may manifest as coma (loss of consciousness) or convulsive fitting (seizures). Life-threatening GI bleeding is also a documented concern, signaled by bloody, black, or tarry stool.

Immediate medical attention must be sought in all suspected overdose situations. The official guidance requires contacting emergency services immediately if the affected individual has collapsed, experienced a seizure, or cannot be awakened. Management is centered on symptomatic and supportive therapy, as the regulatory documents state no specific antidote is known for this medication. Procedures like gastric lavage or activated charcoal administration may be employed as part of the overall supportive care strategy.

Therapeutic Uses of Lotton

What Lotton Treats: Main Uses and Benefits

Lotton (Etodolac) is applied across domains where additional symptomatic support is needed in situations involving distressing symptoms related to inflammatory or irritative states. The medication is relevant for two primary therapeutic categories.


Managing Symptoms of Chronic Inflammatory Joint Diseases

Lotton is generally relevant for managing symptoms of major arthritic conditions, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). It helps address symptom clusters that may become intense or disruptive, and may be applied to help ease persistent joint pain, associated swelling, and stiffness that interfere with daily functioning. This provides support that helps ease the overall symptom burden for patients managing conditions where functional stability becomes affected.


Addressing Acute Pain and Musculoskeletal Discomfort

The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, applied for managing mild to moderate acute pain resulting from temporary injuries or minor procedures. It may assist with addressing the pain and may also help with symptoms related to systemic imbalance, such as fever.


Quick Fact Therapeutic Focus
Symptom Scope Joint pain, swelling, stiffness, and fever
Use Category Support for chronic arthritic symptoms and acute pain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Lotton (Etodolac): Official Regulatory Rules

Official regulatory documents define specific populations who are permitted to use Lotton, those for whom use is restricted or conditional, and those who are absolutely prohibited from use.

Category Official Regulatory Statement
Populations Allowed Adults have established use for all labeled conditions. Older Adults (Geriatric) are permitted but must be monitored due to increased sensitivity and risk of adverse effects.
Use Not Established Pediatric use (below 18 years) for conventional tablets and capsules is not established. Specific extended-release formulations have established use for Juvenile Rheumatoid Arthritis in children 6 to 16 years.

Absolute Contraindications (Prohibited Use)

Lotton must not be used in patients with the following conditions, as stated in regulatory labels:

  • A known hypersensitivity to Etodolac or to any ingredient in the product.
  • A history of aspirin-sensitive asthma or other severe allergic reactions precipitated by any Non-Steroidal Anti-Inflammatory Drug (NSAID).
  • The third trimester of pregnancy (at or after 30 weeks gestation).
  • The peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.
  • A history of active or recurrent peptic ulceration or gastrointestinal bleeding.
  • Severe heart failure, severe hepatic failure, or severe renal failure (as listed in European regulatory documents).

Conditional and Restricted Use

Use is allowed only under special monitoring or restricted circumstances for several groups:

  • Pregnancy: Use at or after 20 weeks gestation should be avoided unless medically necessary, due to the risk of fetal renal dysfunction. Use in the first or second trimester is not recommended unless clearly required.
  • Lactation: Use should be avoided as the medicine may be excreted in human milk.
  • Organ Impairment: Patients with mild-to-moderate renal or hepatic impairment may use the medicine with caution; however, close monitoring is required, as Etodolac may further decrease renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several medicinal products and substances that interact with Lotton (Etodolac), primarily through two mechanisms: additive pharmacodynamic risk and alteration of drug clearance.

Classification Interacting Medicines and Products Mechanism / Restriction Statement
Additive Risk (Not Recommended) Aspirin / Other NSAIDs / COX-2 Inhibitors, Anticoagulants (e.g., Warfarin), Alcohol, SSRIs Co-administration is generally not recommended due to increased risk of serious gastrointestinal bleeding. Alcohol further increases this risk.
Exposure Modification Lithium, Methotrexate, Cyclosporine, Digoxin Lotton officially reduces the renal clearance of Lithium and Methotrexate, and may cause changes in the elimination of Cyclosporine and Digoxin, potentially leading to elevated serum levels.
Pharmacodynamic Antagonism ACE-Inhibitors, ARBs, Diuretics (e.g., Furosemide, Thiazides) Official reports state Lotton may diminish the blood pressure-lowering effect of ACE-Inhibitors/ARBs and reduce the natriuretic (water/salt-reducing) effect of diuretics.

Timing and Administration Constraints

The regulatory label requires specific separation for certain substances:

  • Mifepristone: Lotton must not be administered for 8 to 12 days following the use of Mifepristone due to a risk of reduced clinical effect.

  • Food / Antacids: Administration with food reduces the peak plasma concentration (C max) by approximately one-half, although the overall amount absorbed is unchanged. Antacids similarly decrease the C max by 15% to 20%.

Population-Specific Note

Official documentation notes that the risk for serious gastrointestinal adverse events, which can be compounded by interaction with other agents, is higher in the elderly population.

Mechanism of Action

Preferential Inhibition of the COX-2 Enzyme System

Lotton's core mechanism involves the preferentially selective competitive inhibition of the Cyclooxygenase-2 ( COX-2) enzyme, with the S-enantiomer being the pharmacologically active molecule responsible for binding at the enzyme's active site. This binding modulates the biological pathway responsible for generating prostaglandins, influencing chemical signaling within affected tissues.


Interruption of Prostaglandin Synthesis and Signaling

The drug's molecular activity initiates a cascade that directly suppresses the formation of pro-inflammatory Prostaglandins (such as PGE2) from arachidonic acid. This reduction in key mediators limits their ability to sensitize peripheral nerve endings (nociceptors) and lessens localized tissue responses like vasodilation and edema, resulting in lower prostaglandin-mediated signaling.


Central Modulation of Thermoregulation

Beyond peripheral action, the mechanism extends centrally to affect the hypothalamic thermoregulatory center. By restricting the synthesis of PGE2 in the central nervous system, Lotton influences the hypothalamic set-point, triggering physiological heat-loss mechanisms.

Dosage and Administration Information

Lotton (Etodolac) is intended solely for oral administration, utilizing either immediate-release (IR) capsules/tablets or extended-release (ER) tablets. The usage protocol dictates a dose and frequency dependent on the formulation.

The immediate-release forms are typically dosed in divided schedules, taken two to three times daily for chronic conditions, or every six to eight hours for acute pain. The total daily intake for IR formulations should not exceed 1000 mg. Conversely, the extended-release tablets are designed for convenient once-daily dosing, with adult regimens ranging up to 1200 mg per day.

Procedural guidance requires Lotton to be administered with food or eight to twelve ounces of water; this is a standard condition of use. Crucially, the ER tablets must be swallowed whole and must not be crushed, split, or chewed to maintain the intended release characteristics.

Use for chronic conditions follows the principle of applying the lowest effective dose for the shortest duration necessary. Dosing adjustments are specified for certain populations, such as weight-based regimens for the ER form in pediatric patients with Juvenile Rheumatoid Arthritis. No general dosage changes are required for patients with mild to moderate kidney or liver impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lotton (Etodolac)

The clinical research framework for Lotton was evaluated in studies focusing on outcomes related to physical discomfort in the context of chronic joint conditions and acute pain. The evidence base is derived primarily from controlled trials conducted in adult patient populations.


Evidence for Use in Chronic Inflammatory Joint Conditions

Studies examining patient-reported experiences in conditions characterized by functional limitations, such as Osteoarthritis (OA), were conducted through numerous double-blind, parallel-group studies. These trials focused on outcomes observed in adult patients diagnosed with OA. Research explored outcomes in patient groups who were also evaluated against active comparator agents in trials examining symptom intensity.

For Rheumatoid Arthritis (RA), studies monitored patient-reported experiences, assessing outcomes linked to inflammatory or irritative states. Findings describe patterns observed in the studies that were documented to be consistent with those seen with other active conventional NSAID agents over the evaluation period.


Evidence for Use in Mild to Moderate Acute Pain

For the indication of managing mild to moderate acute pain, the evidence structure relies on single-dose, placebo-controlled trials. Studies monitored outcomes describing episodic or acute changes. Studies examining symptom intensity or variability documented that changes in patient-reported outcomes describing perceived discomfort were noted within approximately 30 to 60 minutes, with the observed change in outcomes typically lasted for several hours.


Areas of Research Uncertainty and Study Limitations

Official regulatory reviews of the available data highlight several limitations. Findings indicate that controlled trials designed to assess outcomes at the highest dosage levels (above 1000 mg/day) are still emerging and were not studied for efficacy as thoroughly as lower dosage regimens. Additionally, the follow-up durations were limited in many controlled studies when considering the chronic nature of conditions like OA and RA. Data for the pediatric population (children under 18) remain insufficient.

Key Studies & References

  1. Etodolac (Lodine) - NIH MedlinePlus Drug Information
  2. DailyMed: ETODOLAC tablet, film coated

Frequently Asked Questions (FAQ)

Common questions about Lotton (FAQ)

Q: How does Lotton compare generally to other medicines for the same condition?

Lotton (Etodolac) is part of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. Studies and official information indicate that its outcomes for treating pain and inflammation are generally consistent with those seen with other active NSAID agents used for the same conditions.

Q: Can Lotton be taken with over-the-counter pain medicines?

Official regulatory labels warn that Lotton is generally not recommended for combination with Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 inhibitors. This is because combining them significantly increases the reported risk of serious gastrointestinal bleeding.

Q: Why is Lotton sometimes restricted for people with kidney problems?

Lotton is prohibited for use in patients with severe kidney failure. For individuals with mild to moderate kidney impairment, official documents indicate that caution and close monitoring are necessary, as Lotton may potentially decrease kidney function over time.

Q: Is Lotton considered a long-term treatment option?

Lotton is indicated in regulatory documents for the management of chronic conditions such as Osteoarthritis and Rheumatoid Arthritis. However, official warnings note that the risk of serious side effects affecting the heart and stomach may increase with the duration of use. Official guidance generally emphasizes using the lowest effective dose for the shortest duration necessary.

Q: What should I look for that indicates Lotton is working?

Lotton is designed to provide symptomatic relief through its core capabilities as an NSAID. This includes properties that lead to less pain (analgesia), reduced swelling (anti-inflammation), and helping to reduce fever (antipyresis).

Q: Is there a generic version of Lotton available?

Yes, the active ingredient in the medicine is Etodolac. Etodolac is the official generic name, and it is available as a generic medicine.

Q: Does Lotton affect blood pressure levels?

According to official warnings, Lotton may potentially lead to the new onset of high blood pressure (hypertension) or the worsening of existing high blood pressure. Additionally, Lotton, like other NSAIDs, has been reported to cause fluid retention (edema).

Q: How is Lotton different from Condition X's older treatments?

The primary difference described in official product information is its mechanism of action, which involves the preferentially selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme system. This is what distinguishes its activity from older, less selective NSAIDs.

Q: Can Lotton be cut in half or crushed? (User understanding of form)

The regulatory instructions for the extended-release (ER) tablets state they must be swallowed whole and are not designed to be cut, crushed, split, or chewed. Altering the ER tablets may change how the medicine is released into the body.

Q: What is the official regulatory classification of Lotton (e.g., controlled substance)?

Lotton, containing the active ingredient Etodolac, is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not designated as a controlled substance by regulatory authorities.

Q: Why do people sometimes stop taking Lotton? (Referring to discontinuation rates in studies)

Official labels describe that permanent discontinuation of the medicine is required if certain serious adverse events occur, such as signs of ischemic colitis or severe complications related to constipation. Regulatory documents also record that patients may discontinue use due to common adverse reactions like abdominal discomfort, nausea, or headache.

Q: What kind of monitoring is usually required while taking Lotton?

Official documentation specifies that close monitoring is indicated for particular patient groups, including older adults and those with mild to moderate kidney or liver impairment. Monitoring of blood counts and liver enzymes may also be performed during treatment.

Q: Does Lotton interact with common cold or flu medications?

Official regulatory warnings advise against taking Lotton with cold or flu medications that contain Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is due to the warning that such combinations significantly increase the reported risk of serious gastrointestinal bleeding.

Q: What is the maximum length of time Lotton has been studied for continuous use?

Regulatory reviews of the available research note that the follow-up durations in many controlled studies were limited when considering the chronic nature of conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

Q: Is it common to feel dizzy or lightheaded after taking Lotton?

Yes, official product information lists dizziness and lightheadedness as common adverse reactions that may occur with Lotton (Etodolac).

Q: Does Lotton cause any changes to sleep patterns?

Changes to sleep patterns, specifically including both insomnia (difficulty sleeping) and somnolence (drowsiness), are listed as reported adverse reactions in official drug documentation.

Q: What happens if I miss a dose of Lotton? (General information)

General regulatory guidance describes the procedure for a missed dose: if it is almost time for the next scheduled dose, the missed dose is typically skipped to maintain the schedule, and double doses are not advised.

Q: How long does Lotton stay in your system?

Regulatory data indicate that the drug's elimination from the system follows a half-life of approximately 6 to 8 hours. The half-life refers to the time it takes for the amount of medicine in the body to be reduced by half.

Q: Are there any known interactions between Lotton and herbal supplements?

Concurrent use with some herbal supplements is associated with warnings. Official information indicates that supplements that affect platelet function or blood clotting, such as turmeric or curcumin, may increase the risk of bleeding associated with NSAIDs.

Q: Why do some official sources refer to Lotton by another name?

Lotton is the brand name given to the medication. Official sources also refer to the medicine by its active ingredient, Etodolac, which is the official generic name for the substance.

Q: What are the signs of a serious allergic reaction to Lotton?

Signs of a serious allergic reaction, as reported in regulatory warnings, can include hives, difficulty breathing, wheezing, or swelling of the face or throat. Severe skin reactions like blistering or peeling are also listed.

Q: Does Lotton affect mood or cause emotional changes?

Yes, adverse reactions reported in official documentation include changes to mood and psychological state, such as feelings of nervousness and depression.

Q: Is it safe to drive while taking Lotton? (General safety concern)

Because Lotton may cause side effects like dizziness, drowsiness, or lightheadedness, official warnings recommend caution. Individuals performing activities that require complete mental alertness, such as driving or operating heavy machinery, should be aware of this potential effect.

Q: Does taking Lotton cause weight gain or weight loss?

Regulatory documentation lists both weight gain and weight loss as reported adverse reactions. The observed weight gain is often related to the potential for the drug to cause fluid retention (edema).

Q: Are skin rashes a known side effect of Lotton?

Yes, skin rashes are listed as a common side effect in official product information. In rare instances, severe skin reactions, such as Stevens-Johnson Syndrome, have also been reported.

Q: Does Lotton have any effect on fertility?

Based on general regulatory warnings associated with this drug class, Lotton may be associated with impaired female fertility. This is a general observation for NSAIDs.

Q: Does Lotton make you more sensitive to sunlight?

Yes, photosensitivity is listed as a reported adverse reaction in official drug documentation. Photosensitivity means the medicine may make the skin more sensitive to sunlight or artificial UV light.

Q: Can Lotton affect the results of lab tests?

Official warnings state that Lotton can affect the results of certain laboratory tests. These effects include the potential for elevations in liver enzymes and sometimes causing a false positive reaction on urine dipstick tests for bilirubin.

Q: Can people with diabetes safely take Lotton?

Official reports indicate that Lotton has been associated with hyperglycemia (high blood sugar) in patients who previously had controlled diabetes. Additionally, Lotton can increase risks when taken with certain diabetes medicines, such as Metformin.

How should Lotton be stored and disposed of?

Storage and Disposal Requirements for Lotton (Etodolac)

Lotton tablets must be stored at controlled room temperature, specifically maintained between 15 C to 30 C (59 F to 86 F). The medication must be protected from both moisture and light, and it is strictly required to keep the product from freezing.

To ensure product stability, the medication must be kept in a well-closed and tightly closed container. In alignment with safety requirements, Lotton must be stored out of the sight and reach of children.

For disposal of unused or expired product, the official procedure prioritizes the use of a drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) in a sealed container and then discarded in the household trash. Lotton is not approved to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lotton found in:

A-Z Index: